Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:31 PM
Ignite Modification Date:
2025-12-24 @ 10:31 PM
NCT ID:
NCT04447235
Eligibility Criteria:
Inclusion Criteria:
* Age greater than or equal to 18 years of age
* Ability to understand and sign informed consent
* Biopsy-proven diagnosis of previous cancer (solid or hematologic disease)
* Participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality.
* Confirmed diagnosis of COVID-19 by the presence of a positive PCR test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on CT scan.
* ECOG performance status 0 to 2
* Patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by:
* Hemoglobin ≥ 9.0 g / dL
* Leukometry\> 2,000 / mm3
* Absolute neutrophil count ≥ 1,500 / mm3
* Platelet count ≥ 100,000 / mm3
* Creatinine clearance ≥ 30 mL / min. Creatinine clearance (CrCl) should be calculated according to the Cockcroft-Gault formula.
* Total bilirubin \<3 x the upper limit of normal (ULN), except for patients with known Gilbert's syndrome.
* Aspartate aminotransaminase (AST) \<3.0 x LSN.
* Alanine aminotransaminase (ALT) \<3.0 x ULN.
Exclusion Criteria:
* Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB).
* Patients who presents with severe conditions at the time of diagnosis requiring ICU admission.
* Prior reaction or intolerance to an ARB or ACE inhibitor.
* Blood pressure less than 110/70 mmHg at presentation
* Potassium greater than 5.0 mEq / L
* Pregnancy or breastfeeding
* Prior reaction to Ivermectin.
* Patient currently enrolled in another research protocol
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04447235
Study Brief:
Protocol Section:
NCT04447235